Antibodies in ADCs are used to precisely target cells for highly cytotoxic antibody compounds. Optimizing antibodies can also drastically reduce the binding of non-specific ADCs and prolong the half-life of ADCs in the blood.
In early studies, the use of mouse antibodies by antibody experts and Elisa often resulted in a severe immune response, and patients developed anti-mouse antibodies that significantly reduced the therapeutic effect. You can search for IHC Services over the internet to get more information.
In recent years, with breakthroughs in antibody technology, it has become possible to use human antibodies or all human antibodies as the main ingredient in ADCs. The most commonly used form of antibody is the IgG family, specifically IgG1.
Antibodies as part of ADC retain their original properties in the body and activate immune functions such as antibody-dependent cellular cytotoxicity (ADCC) and complementary cytotoxicity. In addition, some antibodies have inhibitory receptors or signaling pathways. These independent antibodies are not always useful or complementary to ADCs, while others can cause increased toxicity to the body and attenuate tumor tissue targets and drug internalization of ADCs.
Connectivity
Linkers help bind to antibodies and chemical drugs that directly affect ADC pharmacokinetics, therapeutic index, and therapeutic effect.
The drug-conjugated antibody interface should have the following properties: Stability without releasing drug cytotoxic molecules before reaching their designated target, resulting in non-target toxicity If the target site is endogenous, drug molecules can be released quickly and efficiently.